Question Bank › From candidate to default

From candidate to default

From candidate to default: the company has just been placed inside buyers' own purchasing systems

Calls Tested
498
Answered YES
12
Hit Rate
2.4%
rare by design

Amgen Inc. (AMGN) — this company's answers

NO on the Q3 2018 call 2018-10-30 B+
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从需要说服买家考虑的状态,转变为已获批准、指定、列入清单、合格、注册、报销或预先授权的选择,进入买家自身的采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得公司未来业务的相当一部分可以在没有每次单独销售事件的情况下到来,并且管理层是否传达了这种准入状态是新的,以至于它所带来的大部分销量仍将在报告结果之后出现。 在电话会议中,管理层讨论了多个产品。关键点: - Aimovig:Murdo Gordon 提到“超过 100,000 名患者开始使用 Aimovig”,并提到“我们为帮助患者尽早获得产品而设立的服务一直在解决市场上大量积压的需求”。他还提到“我们正在通过直接面向消费者的电视广告在第四季度初扩大患者教育”。这描述了强劲的上市,但并未明确说明公司已进入一个具体的买方系统(如处方集或报销路径),使得未来业务无需每次销售事件即可自动到来。虽然提到了“有利的批准率”和“患者迅速转向商业覆盖”,但这更多是常规的销售和报销关系,而非新的准入状态。 - Repatha:管理层提到“我们上周做出了一个重要决定,以改善 Repatha 的可及性和可负担性,特别是针对 Medicare Part D 患者”,并推出了新的 NDC,列表价为 5,850 美元,以降低患者的自付费用。这涉及定价和准入,但并未明确说明公司已进入一个具体的系统,使得未来业务自动流动。这更像是定价策略,而非新的准入状态。 - 生物类似药:KANJINTI 和 AMGEVITA 在欧洲上市,但管理层表示“我们很高兴在欧洲推出了我们的第一个商业生物类似药产品”,并提到“我们预计这项业务将在未来几年成为重要的增长驱动力”。这描述了上市,但并未明确说明公司已进入一个具体的采购或报销系统,使得未来业务无需每次销售事件即可自动到来。 - 其他产品:如 Prolia、KYPROLIS 等,管理层讨论了销售增长,但未提及新的准入状态。 管理层没有明确描述公司最近从需要说服买家考虑的状态转变为已获批准、指定、列入清单、合格、注册、报销或预先授权的选择,进入买家自身的系统。虽然提到了报销和准入,但更多是常规的销售和报销关系,而非新的、具体的系统准入。此外,管理层也没有明确传达这种准入状态是新的,以至于大部分销量仍将在未来。 因此,答案应为 NO。

← Back to the full AMGN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company has RECENTLY crossed from being a candidate that buyers must be persuaded to consider into being an APPROVED, SPECIFIED, LISTED, QUALIFIED, REGISTERED, REIMBURSED, OR PRE-AUTHORIZED choice inside buyers' own purchasing, reimbursement, formulary, specification, procurement, network, catalog, or program systems — so that a meaningful portion of the company's future business can now arrive WITHOUT a discrete selling event for each order — AND does management convey that this access status is new enough that most of the volume it will unlock is still ahead of the reported results? Answer YES when management's own words convey this ONE phenomenon, in whatever form fits the industry: the company has moved from candidate toward default inside the routine pathway through which purchases get made. Example forms, all treated equally: being named to an approved or preferred supplier list, procurement schedule, purchasing program, or payer network; being written into specifications, standards, reference designs, configurations, protocols, or bundled defaults; being added to a formulary, reimbursement catalog, coding/payment pathway, formulary-like listing, or provider directory; being qualified onto a customer's, agency's, platform's, or program's roster; or comparable status that inserts the company into the system through which transactions routinely flow. The essential point is the EXCHANGE OF FRICTION STATUS: buying no longer has to be re-argued each time, because the company is now inside the pathway. For YES, management must also convey, directly or plainly in substance, that the status is recent and the flow through it is only beginning — so the results just reported capture little of what this access will bring. One such gateway, or several together, both qualify. Answer NO if the only access described is ordinary selling relationships, routine reseller/distribution agreements, or standard customer wins where each order still must be individually persuaded. NO if the relevant status has existed for years and is simply the company's steady way of going to market, with nothing new about the access. NO if the status is only pending, applied for, hoped for, or contingent on approvals not yet obtained. NO if management merely asserts that the product is "mission-critical," "a standard," or "the default choice" without describing a concrete buyer-side system the company has been placed into. NO if the business flowing through that status is already mature and substantially reflected in current results. NO if the access status or its significance appears only in an analyst's question that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
AZEK The AZEK Company Inc. Q2 2024 2024-05-08 B+
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
INGN Inogen, Inc. Q1 2023 2023-05-05 F
HBB Hamilton Beach Brands Holding Company Q3 2022 2022-11-05 C
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
OPK OPKO Health, Inc. Q1 2022 2022-05-09 D
MGNI Magnite, Inc. Q1 2022 2022-05-04 D
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C

How the model reasoned

PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.

More from the question bank

Paying a named price today to serve businessEarnings outrunning the activityAnalysts converge on an emerging driverWorking harder than they are being paid forNumbers reset the ceilingDeliberately different by designAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.